美国食品和药物管理局建议限制减肥药的复合, 以抑制仿制品. FDA proposes restricting compounding of weight-loss drugs to curb generic versions.

美国食品和药物管理局 (FDA) 建议将流行减肥药的成分从允许药房复合的清单中删除,旨在限制大规模生产仿制品类型. The FDA has proposed removing ingredients for popular weight-loss drugs from a list that allows pharmacies to compound them, aiming to restrict large-scale production of generic-like versions. 预计这一举动将降低廉价替代品的可用性,尽管大多数个性化复合可能不会受到影响. This move is expected to lower the availability of cheaper alternatives, though most personalized compounding may remain unaffected. 机构将在6月29日之前接受公众对该提案的意见. The agency is accepting public comments on the proposal until June 29.